Joshua Richter, MD, a multiple myeloma specialist at Mount Sinai, co-first author on the LINKER-MM1 trial — which supported the FDA approval of linvoseltamab-gcpt (Lynozyfic) — joined Gina Mauro, executive director of Oncology at MJH Life Sciences, for a conversation on where myeloma treatment stands — and where it may be headed.
The discussion covered:
- The word myeloma researchers are starting to say out loud — cure — and whether Richter believes it
- What it felt like to watch linvoseltamab move from trial data to FDA approval
- Trispecific antibodies, which target 3 sites at once, and what they could mean for patients today
- Training at St. Vincent’s in the Village, one of the field’s formative myeloma programs before it closed, and the lessons that era left behind
- How Richter approaches telling a patient that a drug has shown a 100% response rate in early data
The conversation closed with a round of “Myeloma or Myth,” putting 5 things patients commonly believe about the disease to the test — real, false, or somewhere in between.
The Moonlight Shift is available on YouTube and across MJH Life Sciences’ oncology platforms. New episodes, released bi-weekly, feature leading and early-career oncologists from the Tri-State corridor in peer-level conversations about where the field is going — and what it still has to work out.
